Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
15 Outrageous Cosplay Outfits That Will Blow You Away - 2Step by step instructions to Pick A Pre-owned vehicle Stage
- 3Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- 4Explainer-What will change with the US reclassification of marijuana?
- 5Hungary's 'water guardian' farmers fight back against desertification
- Saturn shines with the waxing moon at sunset on Nov. 29
- Pick Your Favored kind of sandwich
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Vote In favor of Your Favored Pet Consideration Administration
- IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- Katz alleges Army Radio workers misled High Court in bid to halt closure
- Striking American and European television Projects: A Survey
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
